A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors

Publications
Written By Martin Lehr
Martin Lehr
Previous

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Next

Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3